Eyelid Closure in Glaucoma Therapy - Full Text View

Sponsored by:	Johns Hopkins University
Information provided by:	Johns Hopkins University
ClinicalTrials.gov Identifier:	NCT00832832

Purpose

This research is being done to determine if closing your eyelids after you take your glaucoma drops makes them more effective in lowering your eye pressure, and to determine if closing your eyelids for 5 minutes is better than closing them for one minute

Condition	Intervention
Glaucoma	Other: Eyelid closure Other: No intervention will be assigned

Study Type:	Interventional
Study Design:	Treatment, Randomized, Single Blind (Investigator), Active Control, Parallel Assignment, Efficacy Study
Official Title:	Eyelid Closure in Topical Glaucoma Therapy

Resource links provided by NLM:

Genetics Home Reference related topics: early-onset glaucoma

MedlinePlus related topics: Glaucoma

U.S. FDA Resources

Further study details as provided by Johns Hopkins University:

Primary Outcome Measures:

Amount of intraocular pressure lowering [ Time Frame: 24 hours ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Amount of intraocular pressure lowering [ Time Frame: 1 hour and one week ] [ Designated as safety issue: No ]

Estimated Enrollment:	60
Study Start Date:	January 2009
Estimated Study Completion Date:	January 2011
Estimated Primary Completion Date:	January 2011 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Eyelid closure: Experimental Eyelids will be closed after administration of eye drop	Other: Eyelid closure Eyelid will be closed after eye drop instillation
No eyelid closure: Active Comparator Eyelids will not be closed after eye drop instillation	Other: No intervention will be assigned No intervention will be assigned to this arm

Show Detailed Description

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Male
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Age over 18 years, use of one of the three topical prostaglandins (latanoprost, travaprost, or bimatoprost), and no other IOP-lowering eye drops for at least one month.

Exclusion Criteria:

Previous laser or incisional surgery for glaucoma, use of punctual plugs, an abnormal slit lamp exam (except for cataract or intraocular lens implant) and incisional eye surgery within the last 6 months.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00832832

Contacts

Contact: Henry D Jampel, MD	410 614 2339	hjampel@jhmi.edu
Contact: Rhonda B Miller, COA	410 409 1177	rhbmiller@jhmi.edu

Sponsors and Collaborators

Johns Hopkins University

Investigators

Principal Investigator:

Henry D Jampel, MD

Johns Hopkins University

More Information

No publications provided

Responsible Party:	Johns Hopkins University ( Dr. Henry D. Jampel )
Study ID Numbers:	NA_00021272
Study First Received:	January 29, 2009
Last Updated:	January 29, 2009
ClinicalTrials.gov Identifier:	NCT00832832 History of Changes
Health Authority:	United States: Institutional Review Board

Keywords provided by Johns Hopkins University:

Glaucoma
Eye drop
Intraocular pressure
Eyelid closure

Study placed in the following topic categories:

Glaucoma
Eye Diseases
Tetrahydrozoline
Hypertension
Ocular Hypertension

Additional relevant MeSH terms:

Glaucoma
Eye Diseases
Ocular Hypertension

ClinicalTrials.gov processed this record on August 28, 2009